SEC Form 4 · accession 0001209191-18-056044

PhaseBio Pharmaceuticals Inc · PHAS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Preclinical and Chem.

Period of report

Oct 22, 2018

Accepted (ET)

Oct 24, 2018 · 4:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001169245

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 22, 2018	C	2,306	—	A	2,306	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrants to Purchase Series B Preferred Stock^F3,F1	$0.12	Oct 22, 2018	M	103	D	—	—	Series B Preferred Stock	103	0	D
Series B Preferred Stock^F1	—	Oct 22, 2018	M	103	A	—	—	Common Stock	103	2,306	D
Series B Preferred Stock^F1	—	Oct 22, 2018	C	2,306	D	—	—	Common Stock	2,306	0	D

F1Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
F2Represents the exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
F3The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.